Matches in SemOpenAlex for { <https://semopenalex.org/work/W2334631240> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2334631240 endingPage "738" @default.
- W2334631240 startingPage "732" @default.
- W2334631240 abstract "Co-administration of anti-hypertension and anti-diabetic drugs is common in clinical settings.In this study, we characterized the drug-drug interactions of losartan (LOS) and glimepiride (GLP) using recombinant cytochrome P450 (CYP) 2C9 enzymes (CYP2C9*1, CYP2C9*3, CYP2C9*13, and CYP2C9*16).Metabolism of losartan by recombinant CYP2C9* 1, CYP2C9*3, CYP2C9*13, and CYP2C9* 16 was inhibited by glimepiride competitively with IC50 values of 0.669 ± 0.055 µM, 0.424 ± 0.032 µM, 2.557 ± 0.058 µM, and 0.667 ± 0.039 µM, respectively. The inhibitory effect of glimepiride on losartan metabolism by CYP2C9*13 was marginal. The apparent Ki value of glimepiride with CYP2C9*3 (0.0416 ± 0.0059 µM) was significantly lower than with CYP2C9*1 (0.1476 ± 0.0219 µM) and CYP2C9*16 (0.2671 ± 0.0456 µM). On the other hand, losartan weakly inhibited the hydroxylation of glimepiride by P450 2C9 enzymes competitively. The potencies for inhibition of glimepiride hydroxylation were determined to be CYP2C9*1~CYP2C9*3~CYP2C9*16 > CYP2C9*13 by 4 µM losartan. No significant inhibition was observed when 0.5 µM losartan was used.Given these results, the potential inhibition of losartan metabolism by CYP2C9*3, CYP2C9*13, and CYP2C9*16 in vivo by glimepiride deserves further investigation. These results may provide valuable information for optimizing the anti-hypertension efficacy of losartan when glimepiride is co-administered to patients." @default.
- W2334631240 created "2016-06-24" @default.
- W2334631240 creator A5000566844 @default.
- W2334631240 creator A5017426380 @default.
- W2334631240 creator A5026399465 @default.
- W2334631240 creator A5040406694 @default.
- W2334631240 creator A5045837907 @default.
- W2334631240 creator A5052189178 @default.
- W2334631240 creator A5064301913 @default.
- W2334631240 creator A5080086185 @default.
- W2334631240 creator A5084257832 @default.
- W2334631240 date "2014-09-01" @default.
- W2334631240 modified "2023-09-23" @default.
- W2334631240 title "Drug-drug interaction of losartan and glimepiride metabolism by recombinant microsome CYP2C9*1, 2C9*3, 2C9*13, and 2C9*16 in vitro" @default.
- W2334631240 doi "https://doi.org/10.5414/cp202071" @default.
- W2334631240 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24986093" @default.
- W2334631240 hasPublicationYear "2014" @default.
- W2334631240 type Work @default.
- W2334631240 sameAs 2334631240 @default.
- W2334631240 citedByCount "7" @default.
- W2334631240 countsByYear W23346312402015 @default.
- W2334631240 countsByYear W23346312402016 @default.
- W2334631240 countsByYear W23346312402017 @default.
- W2334631240 countsByYear W23346312402018 @default.
- W2334631240 crossrefType "journal-article" @default.
- W2334631240 hasAuthorship W2334631240A5000566844 @default.
- W2334631240 hasAuthorship W2334631240A5017426380 @default.
- W2334631240 hasAuthorship W2334631240A5026399465 @default.
- W2334631240 hasAuthorship W2334631240A5040406694 @default.
- W2334631240 hasAuthorship W2334631240A5045837907 @default.
- W2334631240 hasAuthorship W2334631240A5052189178 @default.
- W2334631240 hasAuthorship W2334631240A5064301913 @default.
- W2334631240 hasAuthorship W2334631240A5080086185 @default.
- W2334631240 hasAuthorship W2334631240A5084257832 @default.
- W2334631240 hasConcept C126322002 @default.
- W2334631240 hasConcept C134018914 @default.
- W2334631240 hasConcept C170493617 @default.
- W2334631240 hasConcept C185592680 @default.
- W2334631240 hasConcept C2776307423 @default.
- W2334631240 hasConcept C2777180221 @default.
- W2334631240 hasConcept C2780288358 @default.
- W2334631240 hasConcept C2908929049 @default.
- W2334631240 hasConcept C3946865 @default.
- W2334631240 hasConcept C526171541 @default.
- W2334631240 hasConcept C55493867 @default.
- W2334631240 hasConcept C555293320 @default.
- W2334631240 hasConcept C62231903 @default.
- W2334631240 hasConcept C71924100 @default.
- W2334631240 hasConcept C98274493 @default.
- W2334631240 hasConceptScore W2334631240C126322002 @default.
- W2334631240 hasConceptScore W2334631240C134018914 @default.
- W2334631240 hasConceptScore W2334631240C170493617 @default.
- W2334631240 hasConceptScore W2334631240C185592680 @default.
- W2334631240 hasConceptScore W2334631240C2776307423 @default.
- W2334631240 hasConceptScore W2334631240C2777180221 @default.
- W2334631240 hasConceptScore W2334631240C2780288358 @default.
- W2334631240 hasConceptScore W2334631240C2908929049 @default.
- W2334631240 hasConceptScore W2334631240C3946865 @default.
- W2334631240 hasConceptScore W2334631240C526171541 @default.
- W2334631240 hasConceptScore W2334631240C55493867 @default.
- W2334631240 hasConceptScore W2334631240C555293320 @default.
- W2334631240 hasConceptScore W2334631240C62231903 @default.
- W2334631240 hasConceptScore W2334631240C71924100 @default.
- W2334631240 hasConceptScore W2334631240C98274493 @default.
- W2334631240 hasIssue "09" @default.
- W2334631240 hasLocation W23346312401 @default.
- W2334631240 hasLocation W23346312402 @default.
- W2334631240 hasOpenAccess W2334631240 @default.
- W2334631240 hasPrimaryLocation W23346312401 @default.
- W2334631240 hasRelatedWork W1560543947 @default.
- W2334631240 hasRelatedWork W1969123217 @default.
- W2334631240 hasRelatedWork W2028506307 @default.
- W2334631240 hasRelatedWork W2038571733 @default.
- W2334631240 hasRelatedWork W2048091020 @default.
- W2334631240 hasRelatedWork W2098037832 @default.
- W2334631240 hasRelatedWork W2151218658 @default.
- W2334631240 hasRelatedWork W2176143178 @default.
- W2334631240 hasRelatedWork W2334631240 @default.
- W2334631240 hasRelatedWork W2748952813 @default.
- W2334631240 hasVolume "52" @default.
- W2334631240 isParatext "false" @default.
- W2334631240 isRetracted "false" @default.
- W2334631240 magId "2334631240" @default.
- W2334631240 workType "article" @default.